A Cell-Based Reporter Gene Assay for TNF-α Neutralization: Analytical Qualification and Application to Adalimumab and...

Area of Science:

• Biotechnology
• Immunology
• Pharmacology

Background:

• Adalimumab is a critical biologic therapy for autoimmune diseases.
• Ensuring the quality and consistency of adalimumab and its biosimilars is essential for patient safety and therapeutic efficacy.
• Existing assays may not fully capture the mechanism of action (MoA)-related functional activity.

Purpose of the Study:

• To qualify a mechanism-of-action (MoA)-reflective reporter gene assay (RGA) for adalimumab and biosimilar products.
• To establish a robust method for assessing product quality, comparability, and functional consistency.
• To support lifecycle management of adalimumab therapeutics.

Main Methods:

• The RGA measures TNF-α neutralization by monitoring inhibition of NF-κB signaling.
• Assay qualification focused on system suitability, working range, reproducibility, and intermediate precision.
• The reporter system utilizes a cell-based assay to detect pathway inhibition.

Main Results:

• The RGA demonstrated MoA-relevant readouts of NF-κB pathway inhibition.
• The assay exhibited strong system suitability, a broad working range, and high reproducibility.
• Consistent intermediate precision was observed across repeated measurements, confirming reliability.

Conclusions:

• The qualified RGA is a robust tool for lifecycle management of adalimumab products.
• The assay facilitates quality assessment and comparability studies for adalimumab and biosimilars.
• It enables monitoring of functional consistency across various indications, including rheumatoid arthritis, Crohn's disease, and psoriasis.